CEO interview: Cereno Scientific leaps towards Phase II readout with CS1

Our CEO Sten R. Sörensen comments on the recently published Q2 Report for 2024, the closing of patient recruitment to the Phase II trial of CS1 in rare disease Pulmonary Arterial Hypertension (PAH), for which topline results will be shared in Q3, the Expanded Access Program (EAP) with CS1 in PAH and CS014 entering into a first-in-human Phase I trial in healthy volunteers.

Tune in to hear more!

Watch here